Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C27H30N7OS.K |
| Molecular Weight | 539.737 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[K+].CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4
InChI
InChIKey=OCKQGXSJNJCCDO-UHFFFAOYSA-N
InChI=1S/C27H30N7OS.K/c1-5-6-11-24-28-18(2)23(16-25(36)33(3)4)27(35)34(24)17-19-12-14-20(15-13-19)21-9-7-8-10-22(21)26-29-31-32-30-26;/h7-10,12-15H,5-6,11,16-17H2,1-4H3;/q-1;+1
| Molecular Formula | K |
| Molecular Weight | 39.0983 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C27H31N7OS |
| Molecular Weight | 501.646 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23811571, http://www.boryung.co.kr/eng/product/mainProduct.do
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23811571, http://www.boryung.co.kr/eng/product/mainProduct.do
Fimasartan is a angiotensin II receptor antagonist which was developed in Korea for the treatment of hypertension. The drug is available in different forms: Kanarb, Dukarb (in combination with Amlodipine), Tuvero (in combination with Rosuvastatin). Fimasartan was tested to be effective in Mexican and Russian population and now is being tested in the USA.
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
11.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
66.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
136 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
227 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
601 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
480 mg single, oral dose: 480 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
123 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
224 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
309 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
360 mg 1 times / day multiple, oral dose: 360 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
403 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
360 mg 1 times / day multiple, oral dose: 360 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
227 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
183 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
289.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24084213/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
422 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24084213/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
1864.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24084213/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
281.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25336916/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
457.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25336916/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
98.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
413 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
783 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1116 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2448 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
480 mg single, oral dose: 480 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
636 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
801 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1157 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
360 mg 1 times / day multiple, oral dose: 360 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1441 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
360 mg 1 times / day multiple, oral dose: 360 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1116 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1033 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
932 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24084213/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1509.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24084213/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
4768.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24084213/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
913.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25336916/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1580.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25336916/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.53 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.37 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
9.33 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
10.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
16.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
480 mg single, oral dose: 480 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.73 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
14 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.71 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
360 mg 1 times / day multiple, oral dose: 360 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
17.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
360 mg 1 times / day multiple, oral dose: 360 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
10.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
13.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21910510/ |
240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
7.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24084213/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
8.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24084213/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
8.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24084213/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
9.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25336916/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
11.35 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25336916/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FIMASARTAN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29676941/ |
FIMASARTAN plasma | Homo sapiens |
Doses
| Dose | Population | Adverse events |
|---|---|---|
480 mg single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: |
|
360 mg 1 times / day multiple, oral Studied dose Dose: 360 mg, 1 times / day Route: oral Route: multiple Dose: 360 mg, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
Other AEs: Blood pressure decreased... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Blood pressure decreased | 360 mg 1 times / day multiple, oral Studied dose Dose: 360 mg, 1 times / day Route: oral Route: multiple Dose: 360 mg, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cardioprotective effect of fimasartan, a new angiotensin receptor blocker, in a porcine model of acute myocardial infarction. | 2015-01 |
|
| The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics. | 2014-05 |
|
| Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study. | 2014 |
|
| Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study. | 2013-02 |
|
| Influence of Fimasartan (a Novel AT(1) Receptor Blocker) on Catecholamine Release in the Adrenal Medulla of Spontaneously Hypertensive Rats. | 2013-02 |
|
| Fimasartan, anti-hypertension drug, suppressed inducible nitric oxide synthase expressions via nuclear factor-kappa B and activator protein-1 inactivation. | 2013 |
|
| Pharmacological characterization of BR-A-657, a highly potent nonpeptide angiotensin II receptor antagonist. | 2013 |
|
| Fimasartan, a novel angiotensin II receptor antagonist. | 2012-07 |
|
| Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. | 2012-03 |
|
| Simultaneous determination of fimasartan, a novel antihypertensive agent, and its active metabolite in rat plasma by liquid chromatography-tandem mass spectrometry. | 2011-11 |
|
| Effect of age on the pharmacokinetics of fimasartan (BR-A-657). | 2011-11 |
|
| Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. | 2011-06 |
Patents
Sample Use Guides
Fimasartan is taken as a single oral dose of 60-mg tablet or a single 30-mg intravenous (IV) infusion.
Route of Administration:
Other
Rabbit thoracic aorta cells were incubated with different concentrations of fimasartan ((0.1, 1, 10 nM). At those concentrations fimasartan caused nonparallel rightward shifts in the concentration–contractile response curve to Ang II with a significant reduction in the maximal contractile response to 96.6, 47 and 18%, respectively.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:28:06 GMT 2025
by
admin
on
Mon Mar 31 23:28:06 GMT 2025
|
| Record UNII |
T2ICP7GBBN
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
T2ICP7GBBN
Created by
admin on Mon Mar 31 23:28:06 GMT 2025 , Edited by admin on Mon Mar 31 23:28:06 GMT 2025
|
PRIMARY | |||
|
100000168911
Created by
admin on Mon Mar 31 23:28:06 GMT 2025 , Edited by admin on Mon Mar 31 23:28:06 GMT 2025
|
PRIMARY | |||
|
71465067
Created by
admin on Mon Mar 31 23:28:06 GMT 2025 , Edited by admin on Mon Mar 31 23:28:06 GMT 2025
|
PRIMARY | |||
|
1402813-38-0
Created by
admin on Mon Mar 31 23:28:06 GMT 2025 , Edited by admin on Mon Mar 31 23:28:06 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
|
PARENT -> SALT/SOLVATE |
|
